| 标题 |
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers |
| 网址 | |
| DOI |
10.1158/2159-8290.cd-24-0306
doi
|
| 其它 |
期刊:Cancer Discovery 作者:Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; et al 出版日期:2024-09-05 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人或该文件上传人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)